Literature DB >> 2921157

The proportion of stem cells in murine tumors.

R P Hill1, L Milas.   

Abstract

Considerable evidence suggests that tumors contain only a minority of cells which are capable of regrowing the tumor (ie. tumor stem cells). Since all tumor stem cells must be killed if treatment is to be successful, the number of stem cells in a tumor can be expected to be an important determinant of curability. We have attempted to examine the proportion of stem cells in a variety of murine tumors by making measurements of three different parameters which might be expected to be related to stem cell content: (a) the radiation dose required to control the tumor (TCD50); (b) the number of cells required to transplant the tumor (TD50) and (c) the in vitro plating efficiency. An inverse correlation has been demonstrated between measured TCD50 and TD50 values for two independent groups of murine tumors of varying histopathological type. An inverse correlation was also obtained between the TD50 value and in vitro plating efficiency for a group of spontaneous murine mammary tumors. These correlations most likely reflect underlying differences in the stem cell content of the tumors, and indicate that there is a wide range (2-3 orders of magnitude) of stem cell proportions in different murine tumors, even those which have been transplanted a number of times.

Entities:  

Mesh:

Year:  1989        PMID: 2921157     DOI: 10.1016/0360-3016(89)90353-2

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  21 in total

1.  Spontaneous acquisition of tumorigenicity and invasiveness by mouse lens explant cells during culture in vitro.

Authors:  L Messiaen; S Qian; G De Bruyne; E Boghaert; T Moens; M Rabaey; F Van Roy; M Mareel
Journal:  In Vitro Cell Dev Biol       Date:  1991-05

Review 2.  Individualization of cancer treatment from radiotherapy perspective.

Authors:  Ala Yaromina; Mechthild Krause; Michael Baumann
Journal:  Mol Oncol       Date:  2012-02-09       Impact factor: 6.603

Review 3.  The changing paradigm of tumour response to irradiation.

Authors:  Richard P Hill
Journal:  Br J Radiol       Date:  2016-08-02       Impact factor: 3.039

Review 4.  Radiation oncology in the era of precision medicine.

Authors:  Michael Baumann; Mechthild Krause; Jens Overgaard; Jürgen Debus; Søren M Bentzen; Juliane Daartz; Christian Richter; Daniel Zips; Thomas Bortfeld
Journal:  Nat Rev Cancer       Date:  2016-03-18       Impact factor: 60.716

Review 5.  Improving the Predictive Value of Preclinical Studies in Support of Radiotherapy Clinical Trials.

Authors:  C Norman Coleman; Geoff S Higgins; J Martin Brown; Michael Baumann; David G Kirsch; Henning Willers; Pataje G S Prasanna; Mark W Dewhirst; Eric J Bernhard; Mansoor M Ahmed
Journal:  Clin Cancer Res       Date:  2016-05-06       Impact factor: 12.531

Review 6.  Programmed cell death and radioresistance.

Authors:  R E Meyn; L C Stephens; L Milas
Journal:  Cancer Metastasis Rev       Date:  1996-03       Impact factor: 9.264

7.  Tumor senescence and radioresistant tumor-initiating cells (TICs): let sleeping dogs lie!

Authors:  Gaetano Zafarana; Robert G Bristow
Journal:  Breast Cancer Res       Date:  2010-07-05       Impact factor: 6.466

Review 8.  Radiation responses of cancer stem cells.

Authors:  Erina Vlashi; William H McBride; Frank Pajonk
Journal:  J Cell Biochem       Date:  2009-10-01       Impact factor: 4.429

9.  Immunotherapy of radioresistant mammary tumors with early metastasis using molecular chaperone vaccines combined with ionizing radiation.

Authors:  Desheng Weng; Baizheng Song; Shigeo Koido; Stuart K Calderwood; Jianlin Gong
Journal:  J Immunol       Date:  2013-06-14       Impact factor: 5.422

Review 10.  At the Crossroads of Cancer Stem Cells, Radiation Biology, and Radiation Oncology.

Authors:  Leo E Gerweck; Hiroaki Wakimoto
Journal:  Cancer Res       Date:  2016-02-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.